Goloubeva O - Search Results

1

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Rapoport AP, et al. Among authors: goloubeva o. Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193344 Free PMC article.

2

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ. Bhatnagar V, et al. Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2. Cancer. 2015. PMID: 25469920 Free article. Clinical Trial.

3

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Badros A, et al. Among authors: goloubeva o. Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1. Blood. 2017. PMID: 28461396 Free article. Clinical Trial.

4

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B. Badros A, et al. Among authors: goloubeva o. Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6. doi: 10.3816/CLM.2006.n.061. Clin Lymphoma Myeloma. 2006. PMID: 17229337 Clinical Trial.

5

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Badros AZ, et al. Among authors: goloubeva o. J Clin Oncol. 2005 Jun 20;23(18):4089-99. doi: 10.1200/JCO.2005.14.381. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867202 Clinical Trial.

6

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Badros A, et al. Among authors: goloubeva o. Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921. Cancer. 2007. PMID: 17654660 Free article. Review.

7

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.

Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Badros A, et al. Among authors: goloubeva o. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. doi: 10.1158/1078-0432.CCR-08-2850. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671864 Free PMC article. Clinical Trial.

8

Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression.

Badros AZ, Meddeb M, Weikel D, Philip S, Milliron T, Lapidus R, Hester L, Goloubeva O, Meiller TF, Mongodin EF. Badros AZ, et al. Among authors: goloubeva o. Front Oncol. 2021 Jun 24;11:704722. doi: 10.3389/fonc.2021.704722. eCollection 2021. Front Oncol. 2021. PMID: 34249765 Free PMC article.

9

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Badros A, et al. Among authors: goloubeva o. J Clin Oncol. 2006 Feb 20;24(6):945-52. doi: 10.1200/JCO.2005.04.2465. J Clin Oncol. 2006. PMID: 16484704

10

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.

Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Takebe N, et al. Clin Cancer Res. 2004 Dec 15;10(24):8301-8. doi: 10.1158/1078-0432.CCR-04-0747. Clin Cancer Res. 2004. PMID: 15623606 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page